Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan
· Delayed Price · Currency is TWD 50.40
+0.45 (0.90%)
Apr 29, 2026, 1:30 PM CST
Senhwa Biosciences Revenue
In the year 2025, Senhwa Biosciences had annual revenue of 1.07M TWD with 7.00% growth. Senhwa Biosciences had revenue of 240.00K in the quarter ending December 31, 2025, a decrease of -4.00%.
Revenue
1.07M
Revenue Growth
+7.00%
P/S Ratio
4,172.74
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.46B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACRO Biomedical | 36.50M |
| Medigen Biotechnology | 1.58B |
| Formosa Pharmaceuticals | 9.50M |
| OBI Pharma | 58.58M |
| Pharmosa Biopharm | 67.27M |
| Sagittarius Life Science | 346.08M |
| UnicoCell Biomed | 30.10M |
| Energenesis Biomedical CO.,LTD. | 7.67M |
Senhwa Biosciences News
- 8 months ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga